Latest Prices of Different Versions of Lusutrombopag
Lusutrombopag is a novel oral small‑molecule thrombopoietin receptor agonist (TPO‑RA). It promotes megakaryocyte proliferation and differentiation to enhance platelet production by activating the JAK/STAT and MAPK signaling pathways.
The DaXiong (Laos) version of lusutrombopag has a specification of 3 mg × 7 tablets, with a price of approximately $157 per box. The above price is for reference only; please consult a professional for the specific price.
Dosage and Administration of Lusutrombopag
Recommended Dosage
Initiate lusutrombopag 8–14 days before the scheduled surgery.
The patient should undergo surgery within 2–8 days after the last dose.
The recommended dose is 3 mg orally once daily, with or without food, for 7 consecutive days.
If a dose is missed, the patient should take it as soon as possible on the same day and resume the regular dosing schedule the next day; do not double the dose to make up for a missed dose.
In clinical trials involving patients with chronic liver disease, only the once‑daily, 7‑day single‑course regimen was studied. Lusutrombopag is not recommended for use in patients with chronic liver disease to normalize platelet counts.
Monitoring
Obtain the patient’s platelet count before initiating lusutrombopag treatment and no more than 2 days before surgery.
Adverse Reactions of Lusutrombopag
The most common adverse reaction (≥ 3%) is headache.
Use in Special Populations
Use in Pregnancy
There are currently no available data on the use of lusutrombopag in pregnant women, and the drug‑related risks cannot be assessed. Pregnant women should be advised of the potential risk to the fetus.
Use during Lactation
There are currently no data on whether lusutrombopag is excreted in human milk, its effects on breastfed infants, or its impact on milk production. However, lusutrombopag has been detected in the milk of lactating rats. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during lusutrombopag treatment and for at least 28 days after the last dose.
Use in Pediatric Patients
The safety and efficacy of lusutrombopag in pediatric patients have not been established.
Use in Geriatric Patients
Clinical trials of lusutrombopag did not include a sufficient number of subjects aged 65 years and older to determine whether their responses differ from those of younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients.
